Yvonne Freund-Levi

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
    Yvonne Freund-Levi
    Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Int J Geriatr Psychiatry 23:161-9. 2008
  2. ncbi Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
    Yvonne Freund-Levi
    Department NVS, Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden
    Dement Geriatr Cogn Disord 27:481-90. 2009
  3. ncbi Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
    Inger Vedin
    Department of Medicine, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Lipid Res 51:1179-85. 2010
  4. ncbi Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study
    Inger Vedin
    Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    PLoS ONE 7:e35425. 2012
  5. ncbi Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
    Yvonne Freund-Levi
    Department of Neurobiology, Caring Sciences and Society, Section of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm
    Arch Neurol 63:1402-8. 2006
  6. ncbi Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
    Gerd Faxén Irving
    Department of Neurobiology, Karolinska Institutet, Karolinska University, Hospital Huddinge, Stockholm, Sweden
    J Am Geriatr Soc 57:11-7. 2009
  7. ncbi [Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited]
    Jan Palmblad
    , Karolinska institutet och Karolinska Universitetssjukhuset Huddinge
    Lakartidningen 104:3268-71. 2007
  8. ncbi Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid
    Erik Hjorth
    Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Curr Opin Clin Nutr Metab Care 15:134-43. 2012
  9. ncbi [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]
    Agneta Nordberg
    Geriatriska kliniken, Karolinska Universitetssjukhuset, Huddinge
    Lakartidningen 103:369-71. 2006

Detail Information

Publications9

  1. ncbi Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
    Yvonne Freund-Levi
    Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Int J Geriatr Psychiatry 23:161-9. 2008
    ..An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested...
  2. ncbi Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
    Yvonne Freund-Levi
    Department NVS, Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden
    Dement Geriatr Cogn Disord 27:481-90. 2009
    ..omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer's disease (AD)...
  3. ncbi Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
    Inger Vedin
    Department of Medicine, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Lipid Res 51:1179-85. 2010
    ..The stimulus-specific PGF(2alpha) release from PBMC after 6 months of oral supplementation with the DHA-rich fish oil might be one event related to reduced inflammatory reactions associated with omega-3 fatty acid intake...
  4. ncbi Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study
    Inger Vedin
    Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    PLoS ONE 7:e35425. 2012
    ..Hence, our aim was to determine the effects of 6 mo of dietary supplementation with an n-3 FA preparation rich in DHA on global gene expression in peripheral blood mononuclear cells...
  5. ncbi Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
    Yvonne Freund-Levi
    Department of Neurobiology, Caring Sciences and Society, Section of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm
    Arch Neurol 63:1402-8. 2006
    ..However, positive effects were observed in a small group of patients with very mild AD (MMSE >27 points)...
  6. ncbi Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
    Gerd Faxén Irving
    Department of Neurobiology, Karolinska Institutet, Karolinska University, Hospital Huddinge, Stockholm, Sweden
    J Am Geriatr Soc 57:11-7. 2009
    ..To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer's disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4)...
  7. ncbi [Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited]
    Jan Palmblad
    , Karolinska institutet och Karolinska Universitetssjukhuset Huddinge
    Lakartidningen 104:3268-71. 2007
  8. ncbi Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid
    Erik Hjorth
    Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Curr Opin Clin Nutr Metab Care 15:134-43. 2012
    ..In this review, we present and discuss findings on the modulation of microglial activities by ω-3 FAs in vivo as well as in vitro, and propose mechanisms for their effects...
  9. ncbi [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]
    Agneta Nordberg
    Geriatriska kliniken, Karolinska Universitetssjukhuset, Huddinge
    Lakartidningen 103:369-71. 2006